1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Drugs In Development, 2022, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 4, 4, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Eosinophilic Esophagitis - Overview
- Eosinophilic Esophagitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Eosinophilic Esophagitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
- Eosinophilic Esophagitis - Drug Profiles
- Eosinophilic Esophagitis - Dormant Projects
- Eosinophilic Esophagitis - Discontinued Products
- Eosinophilic Esophagitis - Product Development Milestones
- Featured News & Press Releases
- Jul 14, 2022: Dupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
- Jun 14, 2022: Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases
- Jun 14, 2022: EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
- Jun 01, 2022: Aqilion strengthens its operational team in clinical development prior to planned phase I study with drug candidate for inflammatory diseases
- May 20, 2022: EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
- May 20, 2022: FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder
- May 16, 2022: Revolo Biotherapeutics announces presentations at upcoming medical meetings
- Apr 04, 2022: FDA accepts Dupixent (dupilumab) for priority review in patients aged 12 years and older with eosinophilic esophagitis
- Feb 26, 2022: Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
- Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
- Dec 21, 2021: Allakos announces topline phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS study in patients with eosinophilic gastrointestinal diseases
- Nov 17, 2021: Children's Hospital of Philadelphia receives $2 million gift to jump start new clinical trial for severe food allergies
- Oct 28, 2021: Revolo Biotherapeutics activates clinical sites and opens enrollment in a phase 2 clinical trial of ‘1104 in eosinophilic esophagitis
- Oct 26, 2021: Revolo Biotherapeutics to present at Stifel 2021 Virtual Healthcare Conference
- Oct 25, 2021: EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Eosinophilic Esophagitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Eosinophilic Esophagitis - Pipeline by Adare Pharma Solutions, 2022
- Eosinophilic Esophagitis - Pipeline by Akeso Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Allakos Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Amgen Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Aqilion AB, 2022
- Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, 2022
- Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, 2022
- Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, 2022
- Eosinophilic Esophagitis - Pipeline by Ellodi Pharmaceuticals, 2022
- Eosinophilic Esophagitis - Pipeline by EsoCap AG, 2022
- Eosinophilic Esophagitis - Pipeline by GSK plc, 2022
- Eosinophilic Esophagitis - Pipeline by Invea Therapeutics Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, 2022
- Eosinophilic Esophagitis - Pipeline by Landos Biopharma Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Lanier Biotherapeutics Inc, 2022
- Eosinophilic Esophagitis - Pipeline by LEXEO Therapeutics LLC, 2022
- Eosinophilic Esophagitis - Pipeline by Morphic Therapeutic Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Nexeos Bio, 2022
- Eosinophilic Esophagitis - Pipeline by Pantherics Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Pfizer Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, 2022
- Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Eosinophilic Esophagitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
- Eosinophilic Esophagitis - Pipeline by Serpin Pharma LLC, 2022
- Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
- Eosinophilic Esophagitis - Dormant Projects, 2022
- Eosinophilic Esophagitis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Eosinophilic Esophagitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adare Pharma Solutions
- Akeso Inc
- Allakos Inc
- Amgen Inc
- Aqilion AB
- Banner Life Sciences LLC
- Bristol-Myers Squibb Co
- Calypso Biotech SA
- Ellodi Pharmaceuticals
- EsoCap AG
- GSK plc
- Invea Therapeutics Inc
- Kyowa Kirin Co Ltd
- Landos Biopharma Inc
- Lanier Biotherapeutics Inc
- LEXEO Therapeutics LLC
- Morphic Therapeutic Inc
- Nexeos Bio
- Pantherics Inc
- Pfizer Inc
- Quorum Innovations LLC
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Revolo Biotherapeutics Ltd
- Serpin Pharma LLC
- Suzhou Connect Biopharmaceuticals Ltd
